Literature DB >> 21739269

E-cadherin and β-catenin expression in sebaceous eyelid adenocarcinomas.

Liang Li1, Zhe Zhang, Bin Li, Fei Gao, Liaoqing Li, Jost B Jonas.   

Abstract

BACKGROUND: Since the E-cadherin-catenin complex is of importance in the cancerogenesis of epithelial tumors, we examined the expression of E-cadherin and β-catenin in sebaceous adenocarcinomas of the eyelid and correlated the results with clinicopathological parameters.
METHODS: The study included histological specimen of 32 patients with sebaceous adenocarcinomas of the eyelid. The expression of E-cadherin, β-catenin, and Ki-67 nuclear antigen was analyzed by immunohistochemistry.
RESULTS: The membranous expression of E-cadherin and of β-catenin was reduced in 17 (53%) patients and 18 (56%) patients, respectively, while elevated cytoplasmic levels and a nuclear accumulation of β-catenin were found in 27 (84%) and six (19%) patients, respectively. The low expression of membranous β-catenin was associated with a high degree of tumor infiltration (p = 0.02), high amount of inflammation (p = 0.01), and high degree of poor tumor differentiation (p < 0.001). In a similar manner, a low membranous E-cadherin expression in tumors was significantly associated with poor tumor differentiation (p = 0.001) and high tumor cell proliferation rate (p = 0.004). The Ki-67 proliferation index was significantly higher in the group with low membranous E-cadherin expression than in the group with high membranous E-cadherin expression (62.3 ± 20.8 versus 42.1 ± 15.3; p = 0.004). The membranous E-cadherin expression and the membranous β-catenin expression were significantly associated with each other (Fisher's exact probability test, p = 0.03).
CONCLUSIONS: Sebaceous eyelid adenocarcinomas showed a decrease in the membranous expression of E-cadherin and of β-catenin. These changes were associated with poor tumor differentiation and an increase in the tumor infiltration and inflammation, pointing at a potential role of a low E-cadherin and low β-catenin expression for poor prognosis of sebaceous eyelid adenocarcinomas. Correspondingly, the cell proliferation index and the expression of E-cadherin were inversely correlated with each other. The findings suggest that the immunohistochemical detection of a low E-cadherin and low β-catenin expression may help in the examination and staging of sebaceous eyelid adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739269     DOI: 10.1007/s00417-011-1729-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

Review 1.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

Review 2.  The promise and perils of Wnt signaling through beta-catenin.

Authors:  Randall T Moon; Bruce Bowerman; Michael Boutros; Norbert Perrimon
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 3.  E-cadherin-catenin cell-cell adhesion complex and human cancer.

Authors:  B P Wijnhoven; W N Dinjens; M Pignatelli
Journal:  Br J Surg       Date:  2000-08       Impact factor: 6.939

4.  Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer.

Authors:  K Maruyama; A Ochiai; S Akimoto; S Nakamura; S Baba; Y Moriya; S Hirohashi
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

5.  Sebaceous carcinomas of the ocular adnexa and the Muir-Torre syndrome.

Authors:  P R Cohen
Journal:  J Am Acad Dermatol       Date:  1992-08       Impact factor: 11.527

6.  Decreased E-cadherin but not beta-catenin expression is associated with vascular invasion and decreased survival in head and neck squamous carcinomas.

Authors:  Kevin A Kurtz; Henry T Hoffman; M Bridget Zimmerman; Robert A Robinson
Journal:  Otolaryngol Head Neck Surg       Date:  2006-01       Impact factor: 3.497

7.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

8.  Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.

Authors:  Sam M Wiseman; Hamid Masoudi; Paddy Niblock; Dmitry Turbin; Ashish Rajput; John Hay; Douglas Filipenko; David Huntsman; Blake Gilks
Journal:  Am J Surg       Date:  2006-05       Impact factor: 2.565

Review 9.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.

Authors:  Yu Wei; Jeanne Tran Van Nhieu; Sylvie Prigent; Petcharin Srivatanakul; Pierre Tiollais; Marie-Annick Buendia
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  4 in total

1.  Periocular sebaceous gland carcinoma: A comprehensive review.

Authors:  Kaustubh Mulay; Ekta Aggarwal; Valerie A White
Journal:  Saudi J Ophthalmol       Date:  2013-07

2.  Alteration of the E-Cadherin/β-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma.

Authors:  Hyojin Kim; Seol Bong Yoo; Pingli Sun; Yan Jin; Sanghoon Jheon; Choon Taek Lee; Jin-Haeng Chung
Journal:  Korean J Pathol       Date:  2013-02-25

3.  Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components.

Authors:  Tjinta Brinkhuizen; Karin van den Hurk; Véronique J L Winnepenninckx; Joep P de Hoon; Ariënne M van Marion; Jürgen Veeck; Manon van Engeland; Maurice A M van Steensel
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

4.  Activated hair follicle stem cells and Wnt/β-catenin signaling involve in pathnogenesis of sebaceous neoplasms.

Authors:  Weiming Qiu; Mingxing Lei; Jin Li; Ning Wang; Xiaohua Lian
Journal:  Int J Med Sci       Date:  2014-07-30       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.